Table 2.

Incidence rate of parasitaemia

	Incidence rate per person-year (95% CI)			7-day primaquine vs control		14-day primaquine vs control		7-day primaquine vs 14-day primaquine
	Placebo (n=464)	7-day primaquine (n=935)	14-day primaquine (n=937)	Incidence rate ratio	p value	Incidence rate ratio	p value	Incidence rate ratio	p value
Total patient days of follow-up*	139 258	279 371	287 200	..	..	..	..	..	..
Symptomatic Plasmodium vivax parasitaemia	0·96 (0·83–1·08)	0·18 (0·15–0·21)	0·16 (0·13–0·18)	0·20 (0·15–0·28)	<0·0001	0·18 (0·13–0·24)	<0·0001	1·19 (0·92–1·53)	0·18
Any Plasmodium vivax parasitaemia	1·32 (1·16–1·48)	0·23 (0·19–0·27)	0·19 (0·16–0·23)	0·19 (0·14–0·27)	<0·0001	0·16 (0·12–0·23)	<0·0001	1·17 (0·92–1·48)	0·21
Any Plasmodium falciparum parasitaemia	0·10 (0·05–0·15)	0·15 (0·11–0·19)	0·10 (0·07–0·14)	1·22 (0·80–1·85)	0·36	0·97 (0·63–1·49)	0·89	1·25 (0·89–1·76)	0·19
Parasitaemia of any species	1·42 (1·25–1·59)	0·38 (0·32–0·44)	0·30 (0·24–0·35)	0·25 (0·19–0·33)	<0·0001	0·21 (0·16–0·27)	<0·0001	1·23 (0·99–1·52)	0·061

^*From the first visit to the end of follow-up, or until the last visit if lost.